(Oxford, UK and Conshohocken, US, 16 July 2018) Immunocore Limited, a leading T cell receptor (TCR) company focused on delivering first-in-class biological therapies that have the potential to transform lives, today announces that Paul Fry will step down from his position of Chief Financial Officer on 26 October 2018. Paul will join Vectura Group PLC, the FTSE listed industry-leading inhaled product formulation, device design and development business, as Chief Financial Officer and Executive Board Member. Immunocore is recruiting a successor and hopes to be able to provide an update in due course. Paul will help support a managed transition.
Professor Sir John Bell, Chairman of Immunocore, said: “Paul joined Immunocore in January 2017 and, following our significant financing in 2015, Paul has significantly enhanced the level of governance and control, as well as improved the contribution of Finance to the business as a whole by building a robust team. We wish him well for the future and in his role at Vectura.”
Paul Fry, Chief Financial Officer of Immunocore, added: “Immunocore continues to be one of the most dynamic biotech companies in the international healthcare sector. The Company remains on track to build its portfolio of TCR based programmes into a successful, integrated pharmaceutical company and whilst departing I wish the team all the best for the future
Please click on the link below to download the full Press Release: